According to the recent research report titled ‘Global Biologics CDMO Market (2022 Edition) - Analysis By Type (Mammalian, Non-Mammalian), Product Type (Biologics, Biosimilars), By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2021-2026)’ available with MarketStudyReport, global biologics CDMO market accounted for USD 9.9 billion in 2026 and is poised to have considerable growth through 2026.

Rising geriatric population, technological innovations by the CDMO service providers, increasing number of research and development activities, and growing trend of outsourcing the drug development processes are some of the major factors fueling the global biologics CDMO market growth.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4597185/  

The other factors predominantly driving the market growth are rising disposable income, increasing healthcare expenditure, and growing demand for new therapeutic drugs. Furthermore, with the increasing prevalence of diseases worldwide, there has been spike in demand for novel pharmaceuticals, which in turn will drive the adoption of biologics CDMOs across the globe.

The COVID-19 outbreak has had a positive impact on global biologics CDMO market, owing to increasing demand for vaccinations and therapeutic antibodies. Aside from the economic and social costs, the pandemic has led governments around the world to increase financing for vaccine development, thus contributing toward the overall market remuneration.

While the ongoing crisis has placed a significant burden on the healthcare sector globally, there has been a growing focus to reinforcing the discovery, research, and development activities of numerous medications, further accelerating the growth of the global biologics CDMO industry.

This marketplace is segmented on the basis of product landscape, by type, and regional landscape. By product type, the market is split into biosimilars and biologics market. In terms of type, this industry space is divided into mammalian and non-mammalian type.

The regional terrain of the global biologics CDMO industry is widespread across Asia Pacific, the Middle East & Africa, Europe, North America, and Latin America.

The competitive arena of the global biologics business sphere consists of companies such as Boehringer Ingelheim, Lonza Group AG, AbbVie Inc., Samsung Biologics, WuXi Biologics Inc., AGC Inc., Thermo Fisher Scientific Inc., Toyobo Co. Ltd., ICON Plc, and Fujifilm Diosynth Biotechnologies.